The article reports that Alcon Inc. has partnered with ThromboGenics NV for the development of a non-surgical therapy for the eye disease vitreomacular adhesion (VMA). It notes that concomitant visual symptoms are the basis by Alcon to operate in VMA. It mentions that retinal detachment and bleeding can result from surgery complications for VMA.